Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc., has announced a significant collaboration with Modulant Biosciences LLC. The two companies have signed a binding term sheet that grants Modulant exclusive global rights to develop and commercialize EL-22, a pioneering probiotic approach aimed at muscle preservation in livestock. This strategic partnership allows Northstrive to monetize its intellectual property in the animal health sector. If successfully developed and brought to market, EL-22 could become a long-term revenue-generating asset. The agreement also outlines that Modulant will share a portion of revenues from sublicensing and commercial activities with Northstrive, with specified royalty rates. The parties plan to finalize the definitive licensing agreement in the coming months, pending necessary approvals.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.